Insider Transactions Reported by 21 Insiders of Sensei Biotherapeutics, Inc.

Symbol
SNSE on Nasdaq
Location
Rockville, MD

Insiders trading volume in the past year

Sensei Biotherapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Cambrian BioPharma Inc 10%+ Owner $1,228,724 -$287,265 -19% 09 Dec 2025
James Peyer Other*, 10%+ Owner $1,228,724 -$287,265 -19% 09 Dec 2025
Robert Hamilton Pierce Chief R&D Officer $80,294 15 Feb 2022
Erin Colgan Chief Financial Officer $53,295 15 Feb 2024
John Celebi PRESIDENT AND CEO, Director $50,390 19 Feb 2025
Patrick Stephen Gallagher Chief Business Officer $29,011 15 Feb 2023
Edward van der Horst Chief Scientific Officer $28,462 19 Feb 2025
Christopher Gerry President & PEO $15,173 14 Nov 2025
Deneen Vojta Director $7,592 11 Jun 2024
Samuel Broder Director $7,592 10 Jul 2023
Jessie English Director $7,592 11 Jun 2024
Phillip B. Donenberg Director 13 Feb 2026
Apeiron Investment Group Ltd. 10%+ Owner 01 Jun 2023
William R. Ringo Director 21 May 2025
Bob Holmen Director 21 May 2025
Kristian Humer Director 21 May 2025
Josiah Craver Principal Financial Officer 14 Feb 2025
Stephanie Krebs Chief Business Officer 14 Feb 2025
David G. Gaiero Principal Financial Officer 10 May 2024
Thomas G. Ricks Director 21 May 2025
Anand Kiran Parikh Chief Operating Officer, Director 17 Feb 2026

Recent Insider Transactions by Companies or Individuals for Sensei Biotherapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Anand Kiran Parikh SNSE Employee Stock Option (right to buy) Award 1,239,305 1,239,305 19 Feb 2026 Direct
Anand Kiran Parikh SNSE Employee Stock Option (right to buy) Award 149,206 92,533 17 Feb 2026 Direct
Anand Kiran Parikh SNSE Series B Preferred Stock Award 809,822 809,822 17 Feb 2026 Direct
Phillip B. Donenberg SNSE Stock Option (right to buy) Award 1,900 1,900 13 Feb 2026 Direct
Cambrian BioPharma Inc SNSE Common Stock Options Exercise 0.25% 395 155,983 09 Dec 2025 Direct
Cambrian BioPharma Inc SNSE Common Stock Sale -4.09% $54,575 $8.25 -6,612 155,142 09 Dec 2025 Direct
Cambrian BioPharma Inc SNSE Stock Option (Right to Buy) Options Exercise -100% -395 0 09 Dec 2025 Direct
James Peyer SNSE Common Stock Options Exercise 0.25% 395 155,983 09 Dec 2025 See footnote
James Peyer SNSE Common Stock Sale -2.21% $27,903 $7.96 -3,507 155,142 09 Dec 2025 See footnote
James Peyer SNSE Stock Option (Right to Buy) Options Exercise -100% -395 0 09 Dec 2025 Direct
James Peyer SNSE Common Stock Sale -1.92% $26,672 $8.59 -3,105 158,254 08 Dec 2025 See footnote
Cambrian BioPharma Inc SNSE Common Stock Sale -9.17% $187,390 $11.50 -16,295 161,359 05 Dec 2025 Direct
James Peyer SNSE Common Stock Sale -9.17% $187,390 $11.50 -16,295 161,359 05 Dec 2025 See footnote
Cambrian BioPharma Inc SNSE Common Stock Sale -2.74% $45,300 $9.06 -5,000 177,654 04 Dec 2025 Direct
James Peyer SNSE Common Stock Sale -2.74% $45,300 $9.06 -5,000 177,654 04 Dec 2025 See footnote
Cambrian BioPharma Inc SNSE Stock Option (Right to Buy) Award 19,000 19,000 21 May 2025 Direct
Thomas G. Ricks SNSE Stock Option (Right to Buy) Award 19,000 19,000 21 May 2025 Direct
James Peyer SNSE Stock Option (Right to Buy) Award 19,000 19,000 21 May 2025 See footnote
Kristian Humer SNSE Stock Option (Right to Buy) Award 19,000 19,000 21 May 2025 Direct
Bob Holmen SNSE Stock Option (Right to Buy) Award 19,000 19,000 21 May 2025 Direct
William R. Ringo SNSE Stock Option (Right to Buy) Award 19,000 19,000 21 May 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.